ArticleMedical oncology (Northwood, London, England)2012
Clinical value of Tiam1-Rac1 signaling in primary gallbladder carcinoma.
Article in Medical oncology (Northwood, London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Tiam1 high expression is associated with poor prognosis in solid cancers: A meta-analysis.Medicine · 2019Pooled it
- Decoding Rho GTPase signalling networks in directed cell migration.Frontiers in cell and developmental biology · 2026Review
- A Rac-specific competitive inhibitor of guanine nucleotide binding reduces metastasis in triple-negative breast cancer.Cell reports. Medicine · 2025Article
- Rac1 activation in oral squamous cell carcinoma as a predictive factor associated with lymph node metastasis.International journal of clinical oncology · 2023Article
- Rac1, A Potential Target for Tumor Therapy.Frontiers in oncology · 2021Review
- High Tiam1 expression predicts positive lymphatic metastasis and worse survival in patients with malignant solid tumors: a systematic review and meta-analysis.OncoTargets and therapy · 2019Review
- Prognostic and Clinicopathological Value of Rac1 in Cancer Survival: Evidence from a Meta-Analysis.Journal of Cancer · 2018Review
- TIAM1 inhibits lung fibroblast differentiation in pulmonary fibrosis.Experimental and therapeutic medicine · 2017Article
- IMP2/IGF2BP2 expression, but not IMP1 and IMP3, predicts poor outcome in patients and high tumor growth rate in xenograft models of gallbladder cancer.Oncotarget · 2017Article
- Clinical implication of Tiam1 overexpression in the prognosis of patients with serous ovarian carcinoma.Oncology letters · 2016Article
- Expression of microRNA-10a, microRNA-342-3p and their predicted target gene TIAM1 in extranodal NK/T-cell lymphoma, nasal type.Oncology letters · 2016Article
- The prognostic value of Tiam1 protein expression in head and neck squamous cell carcinoma: a retrospective study.Chinese journal of cancer · 2015Article
- Expression of Tiam1 predicts lymph node metastasis and poor survival of lung adenocarcinoma patients.Diagnostic pathology · 2014Article
- Small interfering RNA targeting Rac1 sensitizes colon cancer to dihydroartemisinin-induced cell cycle arrest and inhibited cell migration by suppressing NFκB activity.Molecular and cellular biochemistry · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tiam1-Rac1 signaling plays an important role in the migration, invasion and metastasis of tumor cells. The aim of the present study was to clarify the clinical value of Tiam1 and Rac1 expression in primary gallbladder carcinoma (PGC). Eighty-six PGC tissues were evaluated by immunohistochemistry for Tiam1 and Rac1 expression. The association of Tiam1 and Rac1 expression with clinicopathological characteristics and the univariate survival analysis for the influence of Tiam1 and Rac1 expression on the overall survival were analyzed. Tiam1 and Rac1 immunoreactivities were observed in 72 (83.7%) and 68 (79.1%) of the 86 PGC cases, but not in the non-neoplastic gallbladder tissues, respectively. The tumors with the positive expression of Tiam1 and Rac1 more frequently showed lymph node metastasis (P = 0.01 and 0.008), lymphovascular invasion (P = 0.009 and 0.01) and recurrence (both P = 0.01), respectively. In addition, the tumors with the positive expression of Tiam1 and Rac1 significantly tended to show deeper invasion depth (P = 0.007 and 0.005) and higher TNM stage (both P = 0.005). The Kaplan-Meier survival curves demonstrated that patients with the positive expression of Tiam1 and Rac1 had a significantly shorter survival time than those patients with their negative expression (both P = 0.01). Multivariate analysis revealed that the positive expression of Tiam1 (P = 0.02) and Rac1 (P = 0.02), as well as TNM stage (P = 0.04), to be independently associated with a poor prognosis of patients with PGC. The data from this study suggest for the first time that Tiam1 and Rac1 are frequently expressed in PGC and are associated with decreased survival of the patients. Therefore, Tiam1 and Rac1 expressions may be independent predictors for the poor prognosis in patients with PGC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.